Shannon E. Boye, Ph.D.
(352) 273-9342 (phone)
(352) 392-3062 (fax)
Academic Research Building, Rm R3-128
Academic Research Building, Rm R2-236
Dr. Shannon E. Boye received her B.S. in marine biology with a minor in chemistry from Fairleigh Dickinson University in 2001. She graduated with a Ph.D. in Neuroscience from the University of Florida in 2006. Her thesis work involved developing viral vectors for the treatment of retinal disease, specifically GUCY2D Leber Congenital Amaurosis (LCA1). Following a postdoctoral fellowship under Dr. William Hauswirth, Dr. Boye was appointed Assistant Professor in the University of Florida’s Department of Ophthalmology (2012). Dr. Boye’s lab currently focuses heavily on three areas of research. (1) Developing a treatment for GUCY2D Leber congenital amaurosis (LCA1)- Her lab has demonstrated the ability to restore retinal function and visually-guided behavior and preserve retinal structure in several animal models of this devastating early-onset retinal dystrophy. Dr. Boye is now moving beyond this proof-of-concept work to develop a clinical-grade AAV vector with which to perform safety studies. Dr. Boye and her collaborators are hopeful that this treatment will be applied to patients within two years. (2) Optimizing AAV vectors to target genes to photoreceptors following intravitreal injection- Because most retinal degenerations are caused by mutations in photoreceptor-specific genes, there is a great need to develop photoreceptor-targeted gene therapies. Of equal importance is the need to develop an injection procedure which is less invasive than the state of the art (subretinal injection), particularly when an underlying genetic defect leads to a degenerative process and a fragile retina prone to further damage upon surgically induced retinal detachment. Using both rational mutagenesis and directed evolution techniques, the Boye lab seeks to develop AAV vectors that possess an enhanced ability to transduce photoreceptor cells, notably foveal cones, following intravitreal delivery. (3) Expanding AAV vector technology- The Boye lab is actively developing novel, dual AAV vector platforms which are capable of delivering large transgenes. Once thought to be a limiting factor for AAV gene delivery, this technology will allow for the treatment of many diseases associated with mutations in large genes (>~5kb). Specific emphasis is placed on myosinVIIa Usher syndrome (USH1b), ABCA4 Stargardt’s disease and congenital stationary night blindness. Dr. Boye’s membership in professional societies includes the Association for Research in Vision and Ophthalmology (ARVO) and the American Society of Gene and Cell Therapy (ASGCT). She currently serves as PI, Co-PI or Co-Investigator on several federally as well as privately funded grants and is actively involved in the University of Florida’s teaching mission. She has authored numerous peer-reviewed manuscripts and textbook chapters, is a member of the NIH Early Career Reviewer (ECR) program and was recently awarded the ARVO Foundation/Merck Innovative Ophthalmology Research Award in Gene Therapy and Eye Disease.
- RO1EY024280 (SE Boye) “Developing Efficient AAV Vectors for Photoreceptor Targeting via the Vitreous” 6/01/14-5/31/19
- Genzyme/Sanofi (SE Boye) “Gene Therapy for LCA1″ 4/01/14-3/31/17
- Foundation Fighting Blindness (SE Boye) Individual Investigator Research Award- “Targeting foveal cones using novel delivery methods and novel AAV serotypes” 6/01/12-6/01/15
- Foundation Fighting Blindness (SE Boye) Individual Investigator Research Award- “Dual AAV vector-mediated therapy for Myosin7A Usher syndrome (USH1B)” 8/01/14-7/31/16
- Foundation Fighting Blindness (Hauswirth and SE Boye) Wynn Gund TRAP (Translational Research Acceleration Program) Award- “Gene Therapy for LCA1″ 10/1/10-9/30/15
- AGTC, Inc. Sponsored Research Agreement (SE Boye) 10/1/14-9/30/16
- AGTC, Inc. Sponsored Research Agreement (Zolotukhin and SE Boye) 10/1/14-9/30/17
Selected Recorded Symposia
- VISIONS 2013 Gene Therapy Clinical Trial Updates
- ARVO 2014 TVST Minisymposium Novel Approaches for Retinal Drug and Gene Delivery
- ARVO 2014 Animal Models Leading to Clinical Trials
- Shannon E. Boye. “Insights gained from gene therapy in animal models of retGC1 deficiency”. Invited review for Frontiers in Molecular Neuroscience (collection on ‘Ca2+ and Ca2+-interlocked membrane guanlyate cyclase modulation of neuronal and cardiovascular signal transduction’) 2014 May 14;7:43. eCollection 2014. Review
- Marina O’Reilly, Howard Federoff, Yuman Fong, Donald B. Kohn, Michael Ahmed, Aravind Asokan, Shannon E. Boye, Ronald Crystal, Satiro De Oliveira, Linda Gargiulo, Scott Harper, Yasuhiro Ikeda, Robert Jambou, Maureen Montgomery, Lawrence Prograis, Eugene Rosenthal, Daniel Sterman, Luk Vandenberghe, Laurie Zoloth, and Jacqueline Corrigan-Curay. Gene Therapy: Charting a Future Course. Summary of a National Institutes of Health Workshop, April 12, 2013. Human Gene Therapy 2014 Apr 28. [Epub ahead of print]
- Shannon E. Boye, Wei-Chieh Huang, Alejandro J. Roman, Alexander Sumaroka, Sanford L. Boye, Renee C. Ryals, Melani B. Olivares, Qing Ruan, Budd A. Tucker, Edwin M. Stone, Anand Swaroop, Artur V. Cideciyan, William W. Hauswirth, and Samuel G. Jacobson. Cone-only Murine Model of Leber Congenital Amaurosis due to CEP290 (cilia-centrosomal protein 290kDa) Mutation: Developing a Proof-of-Concept Strategy. (2014) PLoS One. Mar 26;9(3):e92928
- Frank M. Dyka, Sanford L. Boye, Renee C. Ryals, Vince A. Chiodo, Shannon E. Boye, William W. Hauswirth. Cone specific promoter for use in gene therapy of retinal degenerative diseases. Adv Exp Med Biol. 2014;801:695-701.
- Frank M. Dyka, Sanford L. Boye, Vince A. Chiodo, William W. Hauswirth, Shannon E. Boye. Dual AAV vectors result in efficient expression of an oversized gene, MYO7A. Hum Gene Ther Methods. 2014 Apr;25(2):166-77.
- Elizabeth Simpson, Charles de Leeuw, Frank Dyka, Sanford Boye, Stéphanie Laprise, Michelle Zhou, Alice Chou, Lisa Borretta, Simone McInerny, Kathleen Banks, Elodie Portales-Casamar, Magdalena Swanson, Cletus D’Souza, Shannon Boye, Steven Jones, Robert Holt, Daniel Goldowitz, William Hauswirth, and Wyeth Wasserman. “Targeted CNS Delivery Using Human Minipromoters and Demonstrated Compatibility with Adeno-associated Viral Vectors”. Molecular Therapy Methods (in press)
- Cohen J, Bhullar S, Kasuga D, Boye S, Elhalis H, Kay CN. “Retinal pigment epithelial detachment in ABCA4-associated Stargardt disease.” Ophthalmic Surgery Lasers and Imaging. 2013 Jul-Aug;44(4):401-4.
- Christine N. Kay, Renee C. Ryals, , George V. Aslanidi, , Seok Hong Min, Qing Ruan, Jingfen Sun, Frank M. Dyka, Daniel Kasuga, Andrea E. Ayala, Kim Van Vliet, Mavis Agbandje-McKenna, William W. Hauswirth, Sanford L. Boye, and Shannon E. Boye. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One 2013 Apr 26;8(4):e62097.
- Thomas J. Conlon, Wed-Tao Deng, Kristen Erger, Travis Cossette, Ji-jing Pang, Renee Ryals, Nathalie Clement, Brian Cleaver, Issam McDoom, Shannon E. Boye, Marc C. Peden, Mark B. Sherwood, Corrine R. Abernathy, Fowzan S. Alkuraya, Sanford L. Boye, William W. Hauswirth. Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8.
- Li Jiang, Tansy Z. Li, Shannon E. Boye, William W. Hauswirth, Jeanne M. Frederick, Wolfgang Baehr. RNAi-mediated gene suppression in a GCAP1(L151F) cone-rod mouse model. PLoS One (in press)
- Vanda Lopes*, Shannon E. Boye*, Carrie M. Louie, Sanford Boye, Frank Dyka, Vince Chiodo, William W. Hauswirth, D. S. Williams. “Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus”. Gene Therapy. 2013 Jan 24. doi: 10.1038/gt.2013.3. *equal contribution
- Shannon E. Boye, Sanford L. Boye, Alfred Lewin, William W. Hauswirth. “A Comprehensive Review of Retinal Gene Therapy”. Molecular Therapy. 2013 Mar;21(3):509-19.
- Sanford L. Boye, Igor V. Peshenko, Wei Chieh Huang, Seok Hong Min, Issam McDoom, Xuan Liu, Frank M. Dyka, Tom C. Foster, Yumiko Umino, Sukanya Karan, Samuel G. Jacobson,Wolfgang Baehr, Alexander Dizhoor, William W. Hauswirth and Shannon E. Boye. “AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis”.Human Gene Therapy. 2013 Feb;24(2):189-202.
- Shannon E. Boye, John J. Alexander, Sanford L. Boye, Clark D. Witherspoon, Kristen J. Sandefer, Thomas J. Conlon, Kirsten Erger, Vince A. Chiodo, Mark E. Clark, Christopher A. Girkin, William W. Hauswirth, Paul D. Gamlin. The human rhodopsin kinase promoter in an AAV5 vector confers rod and cone specific expression in the primate retina. Human Gene Therapy 2012 Oct;23(10):1101-15.
- Hong Yu, Rajeshwari D. Koilkonda, Tsung-Han Chou, Vittorio Porciatti, Sacide Ozdemir, Vince Chiodo, Sanford Boye, Shannon Boye, William W. Hauswirth, Nicholas Muzycyka, Alfred S. Lewin, and John Guy. Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber’s hereditary optic neuropathy in a mouse model. Proc Natl Acad Sci U S A (2011). 2012 May 15;109(20):E1238-47
- Jiang L, Zhang H, Dizhoor AM, Shannon E. Boye, Hauswirth WW, Frederick JM, Baehr W. Long term interference gene therapy in a dominant retinitis pigmentosa mouse model. Proc Natl Acad Sci U S A(2011) Nov 8;108(45):18476-81.
- Sanford L. Boye, Thomas Conlon, Kirsten Erger, Renee Ryals, Andy Neeley, Travis Cossette, Jijing Pang, Frank M. Dyka, William W. Hauswirth, Shannon E. Boye. (2011) Long term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest Ophthalmol Vis Sci 52:7098-108. PMID: 21778276
- Renee C. Ryals, Sanford L. Boye, William W. Hauswirth, Shannon E. Boye. (2011) Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines. Mol Vis. 17:1090-102. PMID: 21552473
- M. Mehdi Doroudchi, Kenneth P. Greenberg, Jianwen Liu, Kimberly A. Silka, Edward S. Boyden, Jennifer A. Lockridge, A. Cyrus Arman, Ramesh Janani, Shannon E. Boye, Sanford L. Boye, Gabriel M. Gordon, Benjamin C. Matteo, Alapakkam P. Sampath, William W. Hauswirth, Alan Horsager. (2011) Virally-Delivered Channelrhodopsin-2 Safely and Effectively Restores Visual Function in Multiple Mouse Models of Blindness. Mol Ther. 19:1220-9 PMID: 21505421
- Jijing Pang, Xufeng Dai, Shannon E. Boye, Ilaria Barone, Sanford L. Boye, Song Mao, Drew Everhart, Astra Dinculescu, Li Liu, Yumiko Umino, Bo Lei, Bo Chang, Robert Barlow, Enrica Strettoi, William Hauswirth. Long term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther.19:234-42. PMID: 21139570
- Shannon E. Boye, Sanford L. Boye, Jijing Pang, Renee Ryals, Drew Everhart, Yumiko Umino, Andy W. Neeley, Joseph Besharse, Robert Barlow, William W. Hauswirth.(2010) Functional and behavioral restoration of vision by gene therapy in a mouse model of Leber congenital amaurosis-1 (LCA1). PLoS ONE. 5: e11306. PMID: 20593011
- William A. Beltran, Sanford L. Boye, Shannon E. Boye, Vince A. Chiodo, Gregory M. Acland, Alfred S. Lewin, William W. Hauswirth, Gustavo D. Aguirre. (2010) rAAV2/5 gene-targeting to rods: dose-dependent efficiency and complications associated with different promoters. Gene Therapy. 17:1162-74.
- Shannon E. Boye, Jijing Pang, Bo Lei, Sanford L. Boye, Drew Everhart, Yumiko Umino, Baerbel Rohrer, John Alexander, Jie Li, Bo Chang, Robert Barlow, and William W. Hauswirth. (2010) Self complimentary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of RPE65 deficiency. Gene Therapy. 17:815-26. PMID: 20237510
- Roman AJ, Boye SL, Aleman TS, Pang JJ, McDowell JH, Shannon E. Boye, Cideciyan AV, Jacobson SG, Hauswirth WW. Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis. (2007) Mol Vis. 13:1701-10. PMID: 17960108
- Shannon E. Haire, Pang J, Boye SL, Sokal I, Craft CM, Palczewski K, Hauswirth WW, Semple-Rowland SL.(2006) Light-driven cone arrestin translocation in cones of postnatal guanylate cyclase-1 knockout mouse retina treated with AAV-GC1. Invest Ophthalmol Vis Sci. 47:3745-53. PMID: 16936082
- Williams ML, Coleman JE, Shannon E. Haire, Aleman TS, Cideciyan AV, Sokal I, Palczewski K, Jacobson SG, Semple-Rowland SL. (2006) Lentiviral Expression of Retinal Guanylate Cyclase-1 (RetGC1) Restores Vision in an Avian Model of Childhood Blindness. PLoS Med. 3:e201. Epub 2006 May 23. PMID:16700630
- Jijing Pang, Mei Cheng, Shannon E. Haire, Vicente Planelles and Janet C. Blanks. (2006)Efficiency of lentiviral transduction during development in normal and rd mice. Mol Vis. 12:756-67. PMID: 16862069
- Title: Retinal Disorders: Genetic Approaches to Diagnosis and Treatment Editors: Eric Pierce, Richard Masland, Joan Miller Publisher: Cold Spring Harbor Press Chapter Title: Leber congenital amaurosis due to mutations in GUCY2D Author: Shannon E. Boye 2013
- Title: A Guide to Human Gene Therapy Editors: Herzog and Zolotukhin Publisher: World Scientific Chapter Title: Retinal Diseases Authors: Shannon E Boye, Sanford L Boye, William W. Hauswirth 2009
- Title: Mouse Visual System Editors: Chalupa and Williams Publisher: MIT Press Chapter Title: AAV Gene Therapy in Mouse Models of Retinal Degeneration Authors: SE Boye , SL Boye, WW Hauswirth 2008
- Title: Regenerative Medicine Editors: Robert C. Fisher and Edward W. Scott Publisher: Jones and Bartlett Chapter Title: Retina Authors: Hilda Petrs-Silva, Shannon Boye and William W. Hauswirth